research context only
CJC-1295 Doses Used in Published Studies
What was administered, to which species, by which route — the human pharmacokinetic doses and the handling notes from the literature. No human-use recommendation; there is no approved dose.
CJC-1295 Doses Used in Published Studies
CJC-1295 Doses Used in Published Studies
CJC-1295 dosage in the published record is narrow and entirely investigational. The human pharmacokinetic studies used single subcutaneous doses of 30, 60, or 90 µg/kg in healthy adults [1][8]. Teichman and colleagues administered 30 or 60 µg/kg and tracked GH and IGF-1 over weeks [1]; Ionescu and Frohman used 60 or 90 µg/kg in healthy men [8]. In a GHRH-knockout mouse growth study, 2 µg per dose given once every 24 hours fully normalized body weight and length, while dosing every 48 to 72 hours was progressively less effective — evidence that the long-acting analog's once-daily schedule is sufficient to restore GH-axis-dependent growth [9].
These are doses used in studies, reported here as research methods. They are not a recommendation, and they are weight-normalized trial doses, not fixed amounts. Community and clinic "protocols" for no-DAC Modified GRF (1-29) and for CJC-1295/ipamorelin commonly cite fixed doses in the 100 to 300 µg range, but those figures are not derived from controlled human trials and have no basis in the published pharmacokinetic literature.
How much CJC-1295 should I take?
How much CJC-1295 should I take?
Published human PK studies used single subcutaneous doses of 30, 60, or 90 µg/kg in healthy adults [1][8]; these are research doses, not a human-use recommendation, and there is no approved dosing for CJC-1295. The compound is unapproved, so no regulator has defined a safe or effective dose for any indication.
How much CJC-1295 DAC should I take?
The DAC variant's multi-day half-life of 5.8 to 8.1 days [1] underlies the spaced, once-weekly-style schedules cited in research. Community fixed-dose protocols are not derived from controlled human trials, and the only human dosing on record is the weight-based single-dose PK work — not a maintenance regimen.
What about CJC-1295 and ipamorelin together?
The GHRH-analog-plus-secretagogue pairing rests on a two-receptor synergy rationale (GHRH plus GHRP) [15], but specific combined human dosing is not established in controlled trials. No published study defines a combined dose or schedule for this pairing in healthy adults.
Half-life and the route studied
CJC-1295 DAC has an estimated half-life of 5.8 to 8.1 days in healthy adults, and IGF-1 elevation persisted up to 28 days after multiple doses [1]. The no-DAC form, Modified GRF (1-29), is short-acting — minutes to hours — reflecting native GHRH(1-29) clearance with the protease-resistant substitutions added [7]. Early pharmacokinetic work on native GRF(1-29)NH2 in healthy men established that the unmodified peptide has a short circulating half-life, which is precisely the problem the long-acting program set out to solve [6].
What injection route was studied?
Subcutaneous injection is the primary route in the published literature [1][8]; this is a description of research methods, not administration guidance. Intravenous administration appears only in the early GRF(1-29) pharmacokinetic work [6]. Oral bioavailability is negligible because CJC-1295 is a peptide, so injection is the only route studied for systemic exposure.
How is CJC-1295 reconstituted and stored?
In research handling, the lyophilized peptide is reconstituted with bacteriostatic water and refrigerated; oral bioavailability is negligible, so subcutaneous injection is the route studied. The four substitutions confer DPP-IV and general protease resistance, and DAC conjugation confers the multi-day duration. This describes laboratory handling, not a preparation instruction for use.
Why there is no approved dose
The reason this page can describe doses but not recommend one is simple: no regulator has approved a dose, because CJC-1295 has never cleared the trials that would set one. Human clinical data are limited. The Phase 1 early pharmacokinetic studies in healthy volunteers established GH and IGF-1 kinetics [1][8], and that is the extent of the controlled human record. A ConjuChem Phase 2 trial in HIV-associated visceral obesity (NCT00267527) was discontinued, and the long-acting DAC program did not advance to the large efficacy or long-term safety trials that define a therapeutic dose.
That gap is the single most important thing to carry away from any discussion of CJC-1295 dosage. The weight-based PK doses above tell you what exposure produced a measurable GH response in a small group of volunteers over days. They do not tell you what is safe to use repeatedly, what is effective for any goal, or what a maintenance schedule should be — none of which the literature establishes. The fixed-microgram "protocols" that circulate online fill that vacuum with numbers no controlled trial produced.
What about reconstitution math and handling, in research terms?
In the laboratory, the lyophilized peptide is dissolved in bacteriostatic water, kept refrigerated, and handled as the sensitive protein it is. Because the molecule is a roughly 3.4-kilodalton peptide before albumin conjugation, it is fragile to heat and shear and is not orally active [7]. These are handling notes for a research material, recorded here for completeness, not steps toward administration.